MONDAY, MAY 20, 2013
Remember me:
Just Anticorruption
Companies > GlaxoSmithKline
by Elizabeth Murphy | January 2nd, 2013

Pharmaceutical giant GlaxoSmithKline’s massive health care fraud settlement made the list, too.

by Elizabeth Murphy | December 11th, 2012

The 94 federal prosecuting offices across the country returned more than six times their operating budgets to the U.S. Treasury through collection of fines and penalties.

by Elizabeth Murphy | December 4th, 2012

Officials noted a focus on financial fraud and health care fraud.
UPDATED

by Mary Jacoby | September 11th, 2012

Bradley Birkenfeld’s lawyers say they believe it is the largest whistleblower award ever, though the IRS won’t confirm.

by Mary Jacoby | July 12th, 2012

Just Anti-Corruption has learned that the British anti-fraud agency is prepared to move against the Eurasian Natural Resources Corporation, in headlines in Britain over corruption allegations. But it has not pulled the trigger.

by Elizabeth Murphy | July 2nd, 2012

The Great Britain-based drugmaker admitted to introducing misbranded drugs and failing to report safety data.

by David Stout | May 18th, 2012

Is the biggest corruption vs. anti-corruption drama a long, long way from the Rio Grande?

by Lisa Brennan | March 7th, 2012

Lawyers in several high-profile prosecutions last year explained their strategies at the American Bar Association’s white collar crime meeting in Miami last week.

by David Stout | March 7th, 2012

Do the terms “white collar” and “blue collar” apply in the world of FCPA enforcement?

by Elizabeth Murphy | February 27th, 2012

In FY 2010 and 2011, corporate fraud yielded $2.4 billion in restitution and $16.1 million in fines.

by Elizabeth Murphy | February 14th, 2012

The agencies said they returned $4.1 billion to the U.S. taxpayers in fiscal 2011.

by Elizabeth Murphy | February 1st, 2012

Charles Grassley — the lawmaker most closely associated with the False Claims Act and whistleblower protections — was invited to the event but did not attend. Sen. Patrick Leahy called the False Claims Act a “real success story in government.”

by Main Justice staff | December 19th, 2011

The Justice Department secured more than $3 billion in settlements and judgments in civil cases involving fraud against the government in the fiscal year ending Sept. 30, 2011, Tony West, Assistant Attorney General for the Civil Division, announced today.

by Mary Jacoby | December 9th, 2011

Marc Smolonsky, associate deputy secretary at the Department of Health and Human Services, was among the panelists on Capitol Hill for the Main Justice forum: “What’s Next? Strategies for Improving Compliance with Fraud and Abuse Laws.”

by Christopher M. Matthews | November 16th, 2011

The Justice Department and the Securities and Exchange Commission have been examining since 2004 whether the company violated the Foreign Corrupt Practices Act.

by Christopher M. Matthews | November 8th, 2011

The company has previously disclosed that the SEC and DOJ are investigating it for potential violations of the FCPA.

by Mary Jacoby | November 3rd, 2011

Lauren Stevens was indicted twice in connection with the company’s response to an off-label marketing investigation. A federal judge threw the case out in May.

by David Stout | November 3rd, 2011

The pharmaceutical titan’s settlement marks the biggest ever in the United States over drug marketing.

by Channing Turner | August 23rd, 2011

What does the hiring of Reid Weingarten mean?

by David Stout | June 20th, 2011

U.S. Attorney Rod J. Rosenstein signaled his reservations by withholding his signature.

by David Stout | May 11th, 2011

The acquittal of Lauren Stevens of GlaxoSmithKline was not a proud moment for the department.

by David Stout | May 10th, 2011

The plight of Lauren Stevens has been closely followed by the legal community.

by Christopher M. Matthews | April 29th, 2011

The DOJ’s Criminal Fraud Section and the SEC are investigating at least five other major pharmaceutical companies: GlaxoSmithKline PLC; Baxter International Inc.; Eli Lilly & Co.; Bristol-Myers Squibb Co.; and Merck & Co.

by David Stout | April 15th, 2011

With each new wrinkle the plight of a former GlaxoSmithKline lawyer stirs debate.

by David Stout | April 14th, 2011

The DOJ shows no sign of tiring in its pursuit of Lauren Stevens, accused of misleading regulators.

by David Stout | March 28th, 2011

The plight of GlaxoSmithKline’s ex-counsel continues to draw comment.

by David Stout | March 25th, 2011

A judge delivers a setback for prosecutors in the closely watched case of Lauren Stevens.

by David Stout | March 24th, 2011

Be sure you know which side “your” lawyer is on.

by Christopher M. Matthews | March 7th, 2011

The drug maker has also fallen under the gaze of a separate, industry-wide probe into potential FCPA violations in the pharmaceutical industry currently being conducted by the SEC and the Justice Department.

by Main Justice staff | January 4th, 2011

The list is reasonably current as of Jan. 4, 2010.

BEST FCPA LAWYERS PRACTICE GROUP OF THE YEAR. Main Justice held an awards luncheon in Washington, D.C., to honor top firms in the Foreign Corrupt Practices Act arena. This video shows announcement of the finalists and winner in the Practice Group of the Year category.

 “It ought to be a lesson to people who work on the Hill that when you’re pushing things too far you give up the only power you really have." -- Former DOJ Public Affairs Director Matt Miller on how congressional Republicans lost power over Eric Holder.